| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Linda Booij, Wendelien Merens, C Rob Markus, A J Willem Van der Doe. Diet rich in alpha-lactalbumin improves memory in unmedicated recovered depressed patients and matched controls. Journal of psychopharmacology (Oxford, England). vol 20. issue 4. 2006-08-18. PMID:16174675. |
depression is associated with reduced brain serotonin (5-hydroxytryptamine; 5-ht) function and with cognitive dysfunctions. |
2006-08-18 |
2023-08-12 |
Not clear |
| Amy E Wallace, Julia Neily, William B Weeks, Matthew J Friedma. A cumulative meta-analysis of selective serotonin reuptake inhibitors in pediatric depression: did unpublished studies influence the efficacy/safety debate? Journal of child and adolescent psychopharmacology. vol 16. issue 1-2. 2006-08-18. PMID:16553528. |
a cumulative meta-analysis of selective serotonin reuptake inhibitors in pediatric depression: did unpublished studies influence the efficacy/safety debate? |
2006-08-18 |
2023-08-12 |
Not clear |
| Amy E Wallace, Julia Neily, William B Weeks, Matthew J Friedma. A cumulative meta-analysis of selective serotonin reuptake inhibitors in pediatric depression: did unpublished studies influence the efficacy/safety debate? Journal of child and adolescent psychopharmacology. vol 16. issue 1-2. 2006-08-18. PMID:16553528. |
the aim of this study was to assess whether unpublished trials of serotonin reuptake inhibitors in pediatric depression impacted efficacy or safety conclusions, and to examine the evolution of information contributing to the safety/efficacy debate. |
2006-08-18 |
2023-08-12 |
Not clear |
| Christopher J Kratochvil, Benedetto Vitiello, John Walkup, Graham Emslie, Bruce D Waslick, Elizabeth B Weller, William J Burke, John S Marc. Selective serotonin reuptake inhibitors in pediatric depression: is the balance between benefits and risks favorable? Journal of child and adolescent psychopharmacology. vol 16. issue 1-2. 2006-08-18. PMID:16553525. |
selective serotonin reuptake inhibitors in pediatric depression: is the balance between benefits and risks favorable? |
2006-08-18 |
2023-08-12 |
Not clear |
| Christopher J Kratochvil, Benedetto Vitiello, John Walkup, Graham Emslie, Bruce D Waslick, Elizabeth B Weller, William J Burke, John S Marc. Selective serotonin reuptake inhibitors in pediatric depression: is the balance between benefits and risks favorable? Journal of child and adolescent psychopharmacology. vol 16. issue 1-2. 2006-08-18. PMID:16553525. |
recent controversies surrounding the use of selective serotonin reuptake inhibitors (ssris) have highlighted the need to reassess potential benefits, as well as potential risks of this class of medications in the treatment of pediatric depression. |
2006-08-18 |
2023-08-12 |
Not clear |
| Shauna P Reinblatt, Mark A Riddl. Selective serotonin reuptake inhibitor-induced apathy: a pediatric case series. Journal of child and adolescent psychopharmacology. vol 16. issue 1-2. 2006-08-18. PMID:16553543. |
selective serotonin reuptake inhibitor (ssri)-induced apathy is characterized by a lack of motivation that is not a result of sedation or symptoms of depression. |
2006-08-18 |
2023-08-12 |
Not clear |
| Chiung-Wen Tsao, Yee-Shin Lin, Chwen-Cheng Chen, Chyi-Huey Bai, Shin-Rung W. Cytokines and serotonin transporter in patients with major depression. Progress in neuro-psychopharmacology & biological psychiatry. vol 30. issue 5. 2006-08-18. PMID:16616982. |
cytokines and serotonin transporter in patients with major depression. |
2006-08-18 |
2023-08-12 |
human |
| Richard T Owe. Olanzapine/fluoxetine combination for bipolar depression and other mood disorders: a review. Drugs of today (Barcelona, Spain : 1998). vol 42. issue 3. 2006-08-18. PMID:16628260. |
a combination of the antipsychotic olanzapine and the serotonin reuptake inhibitor fluoxetine has been investigated in both bipolar depression and other affective disorders such as psychotic depression and treatment-refractory depression. |
2006-08-18 |
2023-08-12 |
Not clear |
| J G P Pires, V Bonikovski, H A Futuro-Net. Acute effects of selective serotonin reuptake inhibitors on neuroleptic-induced catalepsy in mice. Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas. vol 38. issue 12. 2006-08-16. PMID:16302101. |
depression found in parkinson disease (pd) usually responds to selective serotonin reuptake inhibitors (ssris). |
2006-08-16 |
2023-08-12 |
mouse |
| Maria Waselus, Juan P Galvez, Rita J Valentino, Elisabeth J Van Bockstael. Differential projections of dorsal raphe nucleus neurons to the lateral septum and striatum. Journal of chemical neuroanatomy. vol 31. issue 4. 2006-08-11. PMID:16540283. |
the dorsal raphe nucleus (drn)-serotonin (5-ht) system has been implicated in acute responses to stress and stress-related psychiatric disorders such as anxiety and depression. |
2006-08-11 |
2023-08-12 |
rat |
| David J Nut. The role of dopamine and norepinephrine in depression and antidepressant treatment. The Journal of clinical psychiatry. vol 67 Suppl 6. 2006-08-11. PMID:16848670. |
through the past several decades, approaches undertaken to clarify the roles of the neurotransmitters norepinephrine, dopamine, and serotonin in depression have included animal studies, human biological and postmortem studies, inferences drawn from antidepressant drug actions, and challenge or depletion studies; most recently, brain imaging studies have proved to be especially informative. |
2006-08-11 |
2023-08-12 |
human |
| Steven Taylor, Murray B Stei. The future of selective serotonin reuptake inhibitors (SSRIs) in psychiatric treatment. Medical hypotheses. vol 66. issue 1. 2006-08-10. PMID:16213665. |
selective serotonin reuptake inhibitors (ssris) are widely prescribed and widely regarded as a first-line treatment for depression. |
2006-08-10 |
2023-08-12 |
Not clear |
| Steven Taylor, Murray B Stei. The future of selective serotonin reuptake inhibitors (SSRIs) in psychiatric treatment. Medical hypotheses. vol 66. issue 1. 2006-08-10. PMID:16213665. |
a review of the empirical literature reveals three main classifications of depression that are relevant to the first hypothesis: (a) more vs. less severe depression, (b) melancholic vs. non-melancholic depression, and (c) depression defined according to associated genetic factors (particularly the long vs. short allele of the serotonin transporter gene promoter). |
2006-08-10 |
2023-08-12 |
Not clear |
| Frank LoVecchio, David Watts, Joseph Winchell, Jason Knight, Tim McDowel. Outcomes after supratherapeutic escitalopram ingestions. The Journal of emergency medicine. vol 30. issue 1. 2006-08-10. PMID:16434330. |
escitalopram (esc) is a new selective serotonin reuptake inhibitor (ssri) used in the treatment of depression. |
2006-08-10 |
2023-08-12 |
Not clear |
| J A J Schmitt, M Wingen, J G Ramaekers, E A T Evers, W J Riede. Serotonin and human cognitive performance. Current pharmaceutical design. vol 12. issue 20. 2006-08-10. PMID:16842171. |
given the mounting evidence for a role of 5-ht in human cognition, reduced 5-ht function could be directly linked to cognitive disturbances in certain conditions, such as in depression and alzheimer's disease (ad). |
2006-08-10 |
2023-08-12 |
human |
| J A J Schmitt, M Wingen, J G Ramaekers, E A T Evers, W J Riede. Serotonin and human cognitive performance. Current pharmaceutical design. vol 12. issue 20. 2006-08-10. PMID:16842171. |
normalizing) 5-ht activity in depression may have specific beneficial effects on cognition, independent of a general relief of depressive symptoms, but this premise needs to be confirmed by larger-scale clinical studies. |
2006-08-10 |
2023-08-12 |
human |
| Kunitoshi Kamijima, Mayumi Aok. Effectiveness of paroxetine in the treatment of obsessive-compulsive disorders. Expert review of neurotherapeutics. vol 6. issue 7. 2006-08-09. PMID:16831110. |
among six different selective serotonin reuptake inhibitors (paroxetine, sertraline, fluoxetine, fluvoxamine, citalopram, escitalopram) that are available worldwide, paroxetine has the broadest treatment spectrum and promises great benefits not only for obsessive-compulsive disorder patients, but also for those with comorbid depression and/or various kinds of anxiety disorders. |
2006-08-09 |
2023-08-12 |
Not clear |
| Norbert Müller, Markus J Schwar. Neuroimmune-endocrine crosstalk in schizophrenia and mood disorders. Expert review of neurotherapeutics. vol 6. issue 7. 2006-08-09. PMID:16831116. |
in addition, the activation of the type 1 and the pro-inflammatory immune responses in major depression result in increased serotonin degradation and a serotonergic deficit. |
2006-08-09 |
2023-08-12 |
Not clear |
| Noelia V Weisstaub, Mingming Zhou, Alena Lira, Evelyn Lambe, Javier González-Maeso, Jean-Pierre Hornung, Etienne Sibille, Mark Underwood, Shigeyoshi Itohara, William T Dauer, Mark S Ansorge, Emanuela Morelli, J John Mann, Miklos Toth, George Aghajanian, Stuart C Sealfon, René Hen, Jay A Gingric. Cortical 5-HT2A receptor signaling modulates anxiety-like behaviors in mice. Science (New York, N.Y.). vol 313. issue 5786. 2006-08-08. PMID:16873667. |
serotonin [5-hydroxytryptamine (5-ht)] neurotransmission in the central nervous system modulates depression and anxiety-related behaviors in humans and rodents, but the responsible downstream receptors remain poorly understood. |
2006-08-08 |
2023-08-12 |
mouse |
| Limei Zhang, Leyla Guadarrama, Aleph A Corona-Morales, Arturo Vega-Gonzalez, Luisa Rocha, Alfonso Escoba. Rats subjected to extended L-tryptophan restriction during early postnatal stage exhibit anxious-depressive features and structural changes. Journal of neuropathology and experimental neurology. vol 65. issue 6. 2006-08-04. PMID:16783166. |
serotonin transmission dysfunction has been suggested to play an important role in depression and anxiety. |
2006-08-04 |
2023-08-12 |
rat |